Company: LNAI
Filing Date: 2025-10-15
Form Type: DEF 14A
Source: 0001731122-25-001378
Chunk: 19

Company: Lunai Bioworks Inc.
Filing Date: 2025-10-15
Form: DEF 14A
Chunk 19
---
 measurements. The Compensation
Committee has the authority to retain and compensate any outside adviser as it determines necessary to permit it to carry out its duties.

The Board has determined that each
member of the Compensation Committee is a “nonemployee director” as that term is defined under Rule 16b-3 of the Exchange
Act and an “outside director” as that term is defined in Treasury Regulation Section 1.162-27(e)(3). The Compensation Committee
meets periodically and at least annually in connection with determining the compensation of management for each fiscal year.

The Compensation Committee met
2 times during the year ended June 30, 2025 and acted by written consent 0 times. The Compensation Committee operates under a charter
that was adopted by our Board and is posted on our website at www.lunaibioworks.com.

The Compensation Committee has
considered the potential risks arising from the Company’s compensation for all employees and does not believe the risks from those
compensation practices are reasonably likely to have a material adverse effect on the Company.

Nominating and Corporate Governance Committee

The members of our Nominating and
Corporate Governance Committee are currently James McNulty, Mark Collins, and Douglas Calder.

<div align='center'>12</div>

The Nominating and Corporate Governance
Committee, as permitted by, and in accordance with, its charter, is responsible for matters related to the selection of directors for
appointment and/or election to the Board. This includes establishing criteria for, identifying and recommending potential candidates for
nomination to serve on the Board, and establishing criteria to consider recommendations from the stockholders of the Company. The Nominating
and Corporate Governance Committee considers and makes recommendations with respect to the independence of all directors.

The Nominating and Corporate Governance
Committee is also responsible for maintaining compliance with applicable corporate governance requirements under the Exchange Act and
the listing standards of NASDAQ. The Nominating and Corporate Governance Committee oversees the evaluation of the Board, including with
respect to corporate governance, and develops and recommends to the Board corporate governance guidelines.

The Nominating and Corporate Governance
Committee acted 1times during the year ended June 30, 2025 by written consent. The Nominating and Corporate Governance Committee operates
under a charter that was adopted by our Board and is posted on our website at www.lunaibioworks.com.

The Board of Directors’ Role in Risk Oversight

The Board, as a whole and also
at the committee level,